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Due to a genetic defect the homozygous Brattleboro rat is unable to synthesize vasopressin gene products 
but still transcribes a mutant vasopressin mRNA from the gene. To study the influence of vasopressin gene 
products on the development of vasopressin gene expression, vasopressin mRNA levels of the supraoptic 
and paraventricular nucleus were measured at fetal day 20, postnatal day 1, 15 and 30 in the Wistar rat 
and in the heterozygous and homozygous Brattleboro rat by Northern blot analysis and in situ hybridiza- 
tion. In the homozygous Brattleboro rat of fetal day 20 and postnatal day 1, no or minute amounts of vaso- 
pressin mRNA were detectable but vasopressin mRNA was readily detectable at postnatal day 15 and 30. 
The Wistar rat and heterozygous Brattleboro rat had abundant vasopressin mRNA at fetal day 20 with 
increasing amounts towards postnatal day 30. The results indicate that vasopressin gene expression in the 
development of the homozygous Brattleboro rat is attenuated, possibly due to the absence of vasopressin 
gene products. 
Vasopressin Gene expression Development (Brattleboro rat) 
1. INTRODUCTION 
The homozygous (di/di) Brattleboro rat has no 
pituitary vasopressin (VP) and consequently suf- 
fers from severe diabetes insipidus [l]. The failure 
of hypothalamic nuclei to synthesize VP has been 
proposed to be due to the one base deletion in the 
VP gene [2]. The mutant VP gene is transcribed 
and spliced correctly, but the mutant mRNA is in- 
efficiently translated [3,4]. There is transcription 
from the mutant VP gene, but it is unknown 
whether this gene is normally regulated. In normal 
animals VP gene expression is strongly enhanced 
during the first month after parturition as in- 
dicated by the VP mRNA content of the 
hypothalamic nuclei, i.e. the supraoptic nucleus 
and paraventricular nucleus [S]. Here we report 
that before birth these nuclei of the homozygous 
(di/di) Brattleboro rat are devoid of detectable VP 
mRNA, in contrast to those of the heterozygous 
(+ /di) Brattleboro and Wistar rats. The data show 
that the expression of the VP gene is attenuated in 
the fetal and neonatal di/di rat, but is subject to 
upregulation during postnatal development. It is 
suggested that this defect may be related to the 
absence of VP gene products during 
ment of the fetal Brattleboro rat. 
the develop- 
2. MATERIALS AND METHODS 
2.1. Animals 
For Northern blot analysis male Wistar rats, 
heterozygous (+ /di) Brattleboro rats and 
homozygous (di/di) Brattleboro rats at the age of 
fetal day 20 (f20), postnatal day 1 (pl), 15 (~15) 
and 30 (~30) were decapitated. Brain sections con- 
taining the supraoptic nucleus (SON) and paraven- 
tricular nucleus (PVN) were isolated from the 
hypothalamus by microdissection [6] and stored at 
- 80°C. 
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For in situ hybridization brain tissue of male 
Wistar rats and homozygous (di/di) Brattleboro 
rats at the age of postnatal day 1 (pl) and 30 (~30) 
was fixed by perfusion with 4% formaldehyde in 
phosphate buffered saline (PBS), left overnight in 
15% sucrose in PBS and stored at - 70°C. 
To exclude maternal effects the offspring of 
both Brattleboro breedings originated from female 
di/di rats sired by di/di and + /di males, respec- 
tively [7]. 
2.2. Northern blot analysis 
From each experimental group consisting of 4 
animals, total RNA was isolated and analyzed on 
Northern blots as described [8]. The relative levels 
of VP mRNA on the Northern blots were quan- 
titated by determination of the absorbance of the 
autoradiographic signals with a videa image 
analysis, processing, evaluating and recording 
system (VIPER, Gesotec, Darmstadt). Auto 
radiographics of dot blots with known amounts of 
Ml3 DNA containing exon C, hybridized with the 
VP-specific 32P-labeled probe, were used for stan- 
dardization of the absorbance. 
2.3. In situ hybridization 
Hybridization on brain slices with single- 
stranded “S-labeled VP-specific DNA probe was 
in 50% formamide and 10% dextran sulphate on 
16 pm cryostat sections for 18 h at 37°C following 
a modified procedure of Lawrence and Singer 
[ 11,121. After hybridization sections were rinsed in 
50% formamide, 2 x SSC at 37°C for 30 min, 
50% formamide, 1 x SSC at 37°C for 30 min, and 
1 x SSC,at room temperature for 30 min. Slides 
were dipped in ethanol, air-dried and exposed to 
Fuji RX X-ray film for 7 days. The VP-specific 
probe was a single-stranded 35S-labeled genomic 
DNA fragment of exon C of the rat VP gene [ 101. 
The probe (314 bases) was enzymatically synthe- 
- TOP 
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Fig. 1. Analysis of VP gene xpression i SON and PVN of male homozygous (di/di), heterozygous (+ /di) Brattleboro 
rats and Wistar rats of fetal day 20 (f20), postnatal day 1 (pl), 15 (~15) and 30 (~30). The autoradiograms of the 
Northern blots show hybridization of VP mRNA in SON (upper) and PVN (lower). 
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Fig.2. In situ hybridization of VP mRNA in hypothalamic brain slices of male homozygous (di/di) Brattleboro rats and 
Wistar rats at the age of postnatal day 1 (pl) and 30 (~30). SON, supraoptic nucleus; PVN, paraventricular nucleus. 
sized by primer extension in the presence of 35S- 
labeled deoxycytidine 5’-triphosphate using a 
recombinant Ml3 clone (MPB-2) as template [8] 
and obtained after restriction digestion and 
polyacrylamide-urea gel electrophoresis as single- 
stranded “S-labeled DNA. 
3. RESULTS 
VP mRNA contents of microdissected SON and 
PVN of male homozygous (di/di), heterozygous 
(+ /di) Brattleboro rats and Wistar rats were 
analyzed at the age of fetal day 20 (f20), postnatal 
day 1 (pl), 15 (~15) and 30 (~30). Total RNA was 
isolated from SON and PVN and analyzed on Nor- 
thern blots in two independent experiments. The 
Northern blots were hybridized with a VP mRNA- 
specific “P-labeled DNA probe [8] and revealed 
that the +/di and Wistar rats contained readily 
detectable amounts of VP mRNA in both SON 
and PVN at all ages. In contrast, the di/di rats had 
no detectable amounts of VP mRNA at f20 in the 
two hypothalamic nuclei. VP mRNA was not 
detectable in the PVN of di/di rats at pl as well, 
but in one of the two experiments avery faint band 
corresponding to VP mRNA was observed in the 
SON of di/di rats at pl (fig.1). At ~15 and p30 the 
VP mRNA content of the SON and PVN of the 
di/di rats had increased as in +/di and Wistar 
rats. Examination of the autoradiograms of the 
Northern blots by computerized image analysis 
showed that the PVN of the di/di rats had no 
detectable VP mRNA at f20 and pl and in the 
SON at f20. At pl the di/di rats had at least 
20-fold lower VP mRNA levels in the SON than 
+ /di and Wistar rats. At p30 the VP mRNA levels 
of SON and PVN of di/di rats were approx. 66% 
of those of the +/di and Wistar rats. 
In situ hybridization was used to evaluate 
anatomically the above observations. For this pur- 
pose brains of di/di and Wistar rats of pl and p30 
were used. In situ hybridization of brain slices was 
performed with a VP mRNA-specific single- 
stranded “S-labeled DNA probe. At pl the di/di 
rat did not contain detectable amounts of VP 
mRNA, while at p30 VP mRNA was detected in 
the SON and PVN (fig.2). In Wistar rats VP 
mRNA was readily detected at pl and ~30. 
4. DISCUSSION 
The presence of readily detectable amounts of 
VP mRNA in the SON and PVN of Wistar and 
heterozygous (+ /di) Brattleboro rats at f20 
demonstrates that the VP gene is expressed 
prenatally. This observation is in agreement with 
the immunohistochemical staining of VP- and 
neurophysin-like material in rat hypothalami as 
early as f16 [13,14] and the detection by radioim- 
munoassays of VP and neurophysin immunoreac- 
tivity around f 14 [ 15,161. It indicates that peptides 
encoded by the VP gene are actually synthesized 
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prenatally. In the homozygous (di/di) Brattleboro 
rat, which fails to synthesize VP, its associated 
neurophysin and glycopeptide [lo], the prenatal 
and early postnatal expression of the mutant VP 
gene differs markedly, since the mutant VP mRNA 
is undetectable around birth. This finding is not 
likely to be attributed to maternal influences, 
either the absence of VP gene products or the 
chronically elevated plasma osmolality of the 
mother, since di/di and +/di rats used in the ex- 
periments were bred in di/di mothers. Therefore 
the attenuated expression of the mutant VP gene 
around birth is an intrinsic property of the fetal 
di/di rat. Apparently, the di/di fetus suffers from 
a defect in the expression of the VP gene either at 
the level of VP gene transcription or VP mRNA 
stability. It may be speculated that the permanent 
absence of VP gene products during the prenatal 
stage of development has suppressed or prevented 
the early expression of the mutant VP gene in the 
di/di Brattleboro fetus. The present results do not 
allow us to conclude whether this is a direct or a in- 
direct consequence of the absence of VP gene 
products. 
The expression of the mutant VP gene of the 
di/di rat is nevertheless subject to enhancement in 
the first postnatal month, as also seen in Wistar [5] 
and + /di controls, indicating that the mutant gene 
sensitive to regulatory factors. This is 
demonstrated by the VP mRNA contents of SON 
and PVN in di/di rats at ~15. In normal animals 
this enhancement matches the maturation of the 
VP neurons at the level of synaptic input and den- 
dritic outgrowth [17,18] and coordinates with the 
onset of kidney function and the involvement of 
VP in the control of diuresis [19]. In di/di Brat- 
tleboro rats the increae in VP mRNA levels coin- 
cide with the manifestation of the diabetes in- 
sipidus syndrome, i.e. polydipsia and polyuria, 
which appears at the onset of the weaning period 
[19]. It could be speculated that the expression of 
the mutant VP gene is stimulated for adaptation to 
impaired osmoregulation. However, at more 
mature stages, i.e. ~30, the VP mRNA levels in the 
di/di rat appeared to be even lower than those in 
the + /di and Wistar rats. Previous studies in di/di 
Brattleboro rats on the basal levels of the mutant 
VP mRNA and the effects of hyperosmolality have 
been contradictory [4,20-241. In our experiments 
the reported elevated plasma osmolality of 30-day- 
104 
old di/di rats [19] did not lead to elevated levels of 
the mutant VP mRNA as compared to + /di and 
Wistar controls. Still, the neurosecretory neurons 
of the hypothalamo-neurohypophyseal system of 
the di/di Brattleboro rat respond to hyper- 
osmolality as indicated by the cellular morphology 
of VP neurons [25] and the elevated levels of OT 
mRNA in the di/di rat (unpublished). Therefore, 
the di/di Brattleboro rat may have another setting 
of the mechanisms regulating the expression of the 
VP gene, e.g. another rate of synthesis or degrada- 
tion of the mutant VP mRNA. Alternatively, it 
cannot be excluded that defects other than the 
single base deletion underlie the attenuated expres- 
sion of the mutant VP gene. Further experiments 
changing the demand of VP, such as possibly VP 
supplementation protocols, may help to unravel 
this question. 
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